NCT06073418 Dietary Habits, Nutritional Knowledge and Physical Activity Assessment in Early Stage Breast Cancer Patients
| NCT ID | NCT06073418 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centro di Riferimento Oncologico - Aviano |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,098 participants |
| Start Date | 2022-10-28 |
| Primary Completion | 2032-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,098 participants in total. It began in 2022-10-28 with a primary completion date of 2032-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The advances in early detection coupled with improvements in treatments have led to an ever increasing number of breast cancer survivors. New methods to improve outcomes, including strategies aimed at improving the quality of life and reducing the risk of other diseases, may complement the currently available treatment options. In particular, interventions targeting diet, weight and physical activity can reduce the risk of cancer occurrence, prevent cancer recurrence, and improve survival and the quality of life.This cross-sectional, prospective, observational study aims at evaluating dietary habits and nutritional knowledge in patients with early hormone receptor positive and hormone receptor negative breast cancer.
Eligibility Criteria
Inclusion Criteria: * Patients with surgically removed early stage (I-IIIa) hormone receptor-positive or hormone receptor negative breast cancer. Patients with hormone receptor-positive breast cancer can be in treatment with endocrine therapy; patients with hormone receptor-negative tumors have to be in follow-up. Concomitant use of targeted therapies with anti-hormonal agents is allowed only in adjuvant setting * Female patients ≥18 years of age. * Written informed consent must be obtained before any study-related assessment is performed Exclusion Criteria: * Patients with advanced/metastatic breast cancer. * Patients with early breast cancer receiving (neo)adjuvant chemotherapy or anti-HER2 agents * Patients receiving active treatment for secondary primary tumors (excluding basal cell carcinoma or in situ neoplasias)
Contact & Investigator
Mattia Garutti, MD
PRINCIPAL INVESTIGATOR
IRCCS-Centro di Riferimento Oncologico (CRO), Aviano (PN)
Frequently Asked Questions
Who can join the NCT06073418 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06073418 currently recruiting?
Yes, NCT06073418 is actively recruiting participants. Contact the research team at mattia.garutti@cro.it for enrollment information.
Where is the NCT06073418 trial being conducted?
This trial is being conducted at Aviano, Italy.
Who is sponsoring the NCT06073418 clinical trial?
NCT06073418 is sponsored by Centro di Riferimento Oncologico - Aviano. The principal investigator is Mattia Garutti, MD at IRCCS-Centro di Riferimento Oncologico (CRO), Aviano (PN). The trial plans to enroll 1,098 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.